Advertisement

Pharmacokinetics and side-effects of clonazepam and its 7- amino-metabolite in man

  • O. Sjö
  • E. F. Hvidberg
  • J. Naestoft
  • M. Lund
Originals

Summary

Clonazepam (CNP) and its principal metabolite in plasma, 7-amino-CNP (ACNP), have been investigated in a prospective study of 27 newly diagnosed epileptics and correlated with specified side-effects. At a daily dose of 6 mg, the average plasma levels of both substances were about 50ng/ml, and individual values ranged from 30 to about 80ng/ml. There was a linear correlation between changes in dose and the resulting plasma levels, which indicates first order elimination kinetics. Side-effects were frequent, but neither their severity nor their occurrence could be related to plasma levels or to the rate of increase in plasma concentration of the drug. Three out of five patients who developed serious dysphoria had significantly high CNP levels. The concentration of ACNP was considerably increased in four patients who subsequently suffered from withdrawal symptoms. Drug interaction with diphenylhydantoin, i.e. decreased CNP level, was observed in all five patients who received both compounds. In general it is not yet possible to define an upper limit for the plasma levels of CNP and ACNP at which toxicity occurs. In patients treated with conventional doses of CNP, measurement of plasma concentration is not required, except in special circumstances, because of the lack of correlation between plasma level and side-effects.

Key words

Clonazepam 7-amino-clonazepam pharmacokinetics side-effects man 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Bladin, P.: The use of clonazepam as an anticonvulsant — clinical evaluation. Med. J. Aust.1 683–688 (1973)Google Scholar
  2. Edwards, V.E., Eadie, M.J.: Clonazepam, a clinical study of its effectiveness as an anticonvulsant. Proc. Austral. Ass. Neurol.10 61–66 (1973)Google Scholar
  3. Elian, M., Lund, M. and Melsen, S.: The rate of dosage increase of clonazepam. Acta neurol. scand.49 suppl.53, 32–35 (1973)Google Scholar
  4. Eschenhof, E.: Untersuchungen über das Schicksal des Antikonvulsivums Clonazepam im Organismus der Ratte, des Hundes und des Menschen. Arzneimittel. — Forsch.23 390–400 (1973)Google Scholar
  5. Gastaut, H., Catier, J., Dravet, C., Roger, J.: Exceptional anticonvulsive properties of a new benzodiazepine. Mod. Probl. Pharmacopsychiatry: Epilepsy.4 261–269 (1970)Google Scholar
  6. Ghosh, B.K.: Sequential Tests of Statistical Hypotheses. London: Addison-Wesley Publishing Company 1970Google Scholar
  7. Huang, C.Y., Mc Lead, J.G., Sampson, D., Hensley, J.: Clonazepam in the treatment of epilepsy. Proc. Austral. Ass. Neurol.10 67–74 (1973)Google Scholar
  8. Lehtovaara, R.: A clinical trial with clonazepam (Ro 5-4023). Acta neurol. scand.49 suppl.53, 77–81 (1973)Google Scholar
  9. Lund, M. and Trolle, E.: Clonazepam in the treatment of epilepsy. Acta neurol. scand.49 suppl.53, 82–90 (1973)Google Scholar
  10. Mattson, R.H. In: Antiepileptic Drugs (Ed. Woodbury, D.M., Penry, J.K. and Schmidt, R.P.), chap. 57. New York: Raven Press 1972Google Scholar
  11. Mikkelsen, B., Birket-Smith, E.: A clinical study of the benzodiazepine Ro 5-4023 (clonazepam) in the treatment of epilepsy. Acta neurol. scand.49 suppl.53, 91–96 (1973)Google Scholar
  12. Naestoft, J., Lund, M., Larsen, N.-E., Hvidberg, E.F.: Assay and pharmacokinetics of clonazepam in humans. Acta neurol. scand.49 suppl.53, 103–108 (1973)Google Scholar
  13. Naestoft, J., Larsen, N.-E.: Quantitative determination of clonazepam and its metabolites in human plasma by gas-chromatography. J. Chromatogr.93 113–122 (1974)Google Scholar

Copyright information

© Springer-Verlag 1975

Authors and Affiliations

  • O. Sjö
    • 1
    • 2
  • E. F. Hvidberg
    • 1
    • 2
  • J. Naestoft
    • 1
    • 2
  • M. Lund
    • 1
    • 2
  1. 1.Departments of Neurology and Clinical ChemistryGlostrup HospitalCopenhagenDenmark
  2. 2.Clinical Pharmacology Research UnitDanish State Medical Research CouncilCopenhagenDenmark

Personalised recommendations